Loading…
Early cancer-detection company developing blood-based, AI-driven screening tests, starting with colorectal cancer.
Early cancer-detection company developing blood-based, AI-driven screening tests, starting with colorectal cancer.
In one line: An AI-driven, blood-test rival to Exact Sciences' Cologuard.
Moat: narrow (data, IP / patents). AI/multiomics platform trained on large blood-sample datasets aims to detect early-stage cancer signals.
Headquarters: South San Francisco, California · Founded: 2013 · Employees: 3
Size Freenome (FRNM) is a United States Health Care company (Medical Specialties) with a market value of $1.09B, the 2193rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $10.18 on 6 Nov 2026.
Valuation It trades at 1.33× book value against a peer median of 3.88× (3rd cheapest of 21).
Price implies The share price implies a return on equity of about 9.4%; Freenome delivers -0.9%, so the price asks more than the business earns today.
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | $0 | $0 | $0 |
| EBITDA | -$4.33M | -$2.98M | -$494,000 |
| Net income | -$762,626 | $837,468 | $1.91M |
| Free cash flow | -$907,040 | -$864,650 | -$713,260 |
| Capital expenditure | $0 | $0 | $0 |
| Total debt | $0 | $0 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE |
|---|---|---|---|---|---|---|
| Freenome FRNM | $1.09B | n/a | n/a | -1% | 1.33× | 9.4% |
| Guardant Health GH | $20.2B | +58% | +43% | n/a | n/a | n/a |
| Natera NTRA | $44.8B | +60% | +38% | -13% | 24.49× | 238.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | FRNM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -35.6% | +1.2% | lowest of 21 |
| Return on equity | -0.9% | 0.3% | 10th lowest of 21 |
| Price / book | 1.33× | 3.88× | 3rd cheapest of 21 |
| ROE the price implies | 9.4% | 26.4% | 2nd least demanding of 20 |
| ROE delivered | -0.9% | 0.2% | 10th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| Freenome FRNM | United States | $1.09B | n/a | n/a | -1% | 1.33× | 9.4% | -0.9% |
| SI-BONE SIBN | United States | $1.09B | +98% | +14% | -8% | 5.91× | 32.9% | -7.7% |
| PHC 6523.T | Japan | $1.09B | +36% | +3% | 6% | 1.01× | 8.4% | 6.0% |
| Amoy Diagnostics 300685.SZ | China | $1.10B | -14% | +7% | 18% | 3.71× | 30.1% | 17.6% |
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 23% | 10.37× | 69.6% | 23.4% |
| Tinavi Medical Technologies 688277.SS | China | $1.08B | -30% | -2% | -14% | 6.15× | 48.1% | -13.6% |
| INKON Life Technology 300143.SZ | China | $1.08B | -14% | +22% | 3% | 2.98× | 25.1% | 3.4% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -8% | 1.72× | 11.9% | -7.7% |
| L&C BIO 290650.KS | South Korea | $1.07B | -17% | +53% | -47% | 4.04× | 26.6% | -47.0% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 7% | 2.07× | 13.1% | 6.6% |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 12% | 4.12× | 24.9% | 12.4% |
| Edan Instruments 300206.SZ | China | $1.05B | -19% | +14% | 16% | 2.99× | 26.4% | 16.5% |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 1% | 0.98× | 11.1% | 1.2% |
| Alphatec ATEC | United States | $1.15B | -1% | +15% | -308% | 89.96× | n/a | -308.1% |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -52% | 8.78× | 57.0% | -52.5% |
| Inno Laser Technology 301021.SZ | China | $1.16B | -18% | +17% | 8% | 7.21× | 95.2% | 7.8% |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -48% | 9.02× | 91.9% | -48.0% |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -30% | 3.47× | 24.6% | -30.2% |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -4% | 2.11× | 17.5% | -4.2% |
| Artivion AORT | United States | $985M | -20% | +16% | -1% | 2.21× | 21.5% | -0.7% |
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 3% | 7.56× | 58.9% | 3.1% |